Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
SGLT2 inhibitors lower kidney failure risk in type 2 diabetes patients
This systematic review and meta-analysis of 10 studies synthesized evidence on dapagliflozin for renal outcomes in patients with type 2 diab…
A review of ten studies shows these drugs reduce kidney failure risk in people with type 2 diabetes and kidney disease.
Systematic review links hypertension, diabetes, and pulmonary inflammation; SGLT2 inhibitors show potential
Why Your Blood Pressure Might Be Hurting Your Lungs
This systematic review of 48 articles explores the interplay between arterial hypertension, diabetes mellitus, and pulmonary inflammation. I…
High blood pressure and diabetes don't just affect your heart and sugar levels; they team up to harm your lungs.
Jordan guideline review highlights SGLT2 inhibitor access barriers for heart failure patients
Heart Failure Patients Face New Insurance Hurdle for Key Drug
This mixed-methods study and guideline analysis surveyed 312 physicians in Jordan regarding prescribing decisions and insurance authorizatio…
A new study reveals that insurance rules, not medical science, are stopping heart failure patients from getting a proven treatment.
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals.
No More Bone Fear With New Diabetes Drug
This meta-analysis evaluated adjunctive SGLT2 inhibitor therapy in 6,731 patients with type 1 diabetes mellitus receiving insulin-based ther…
Many people with type 1 diabetes worry about their bones.
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease.
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition. It argues that i…
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S. EHR network found higher maximum semaglutide dose w…
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients
Older Adults With Heart Failure May Gain Years From This Pill
A systematic review and meta-analysis of 20,844 patients aged 65+ with heart failure found SGLT2 inhibitors were associated with reduced all…
A pooled look at 10 studies in over 20,000 older adults shows SGLT2 inhibitors cut the risk of dying from any cause by about a fifth — and t…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
Self-management and glycemic control linked to lower MCI risk in rural elderly with type 2 diabetes
Better diabetes self-care linked to lower cognitive decline risk in rural elderly study
A cohort study of 232 rural Chinese elderly with type 2 diabetes found improved self-management behaviors, fewer depressive symptoms, and be…
Better diabetes self-care and mood control in older adults with type 2 diabetes were linked to a lower risk of memory problems in a rural Ch…